key: cord-0766744-qqpboyw5
authors: Winchester, Stephen; John, Sarah; Jabbar, Kashif; John, Isaac
title: Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection
date: 2021-05-13
journal: J Infect
DOI: 10.1016/j.jinf.2021.05.009
sha: 87e5d40c7ea3d5ee85e63839bf8f72410880ca67
doc_id: 766744
cord_uid: qqpboyw5

Baek et al(1) investigated the duration of COVID-19 virus shedding in infected patients and demonstrated that even in patients demonstrating prolonged viral clearance, the virus was no longer viable after 15 days post onset of symptoms. Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray. Our study recruited 80 participants who were divided into a NONS treatment arm or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection.

SARS-CoV-2; Prevention; Antiviral; Antimicrobial; COVID-19; Nitric Oxide; Coronavirus; Treatment; Nasal Spray

Baek et al 1 investigated the duration of COVID-19 virus shedding in infected patients and demonstrated that even in patients demonstrating prolonged viral clearance, the virus was no longer viable after 15 days post onset of symptoms. Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray. Our study recruited 80 participants who were divided into a NONS treatment arm or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection.

The coronavirus (COVID-19) pandemic has had a profound impact on the world, resulting in a worldwide death toll of over 2.6 million and global cases in excess of 119 million as at March 2021. 2 These figures demonstrate the necessity of rapidly developing new and effective ways in which to control and treat the virus in support of the emergency use of already-available COVID-19 vaccines. 3 There are currently no evidence-based treatments for mild COVID-19 infection. This doubleblind phase IIb clinical trial uses placebo controls to evaluate the efficacy of nitric oxide in the treatment of mild, symptomatic COVID-19 infection in the form of a self-administered nasal spray. Nitric oxide (NO) is a free radical gas molecule involved in innate immunity, as well as wound healing, vasodilation, neurotransmission, and angiogenesis. 4 It is produced physiologically and has been shown to exhibit a number of antimicrobial actions both in vitro and in vivo. 5, 6, 7 

This trial was carried out at Ashford and St. Peter's Hospitals NHS Foundation Trust (ASPHFT). 80 adults (18-70 years) who were isolated with mild COVID-19 infection confirmed by laboratory SARS-CoV-2 RT-PCR nasal and throat swab within the 48 hours of randomisation were eligible for recruitment. Participants were randomised 1:1 to receive NONS (n=40) or placebo (n=40). The nasal sprays were self-administered at a rate of 5-6 times daily at 4 sprays (each 120-140μL of solution) per dose for 9 days.

Treatment with NONS or placebo commenced on day 1. Participants took self-sampled nasal and throat swabs on days 0, 2, 4, and 6 in the mornings, prior to treatment. Quantitative RT-PCR was carried out at Berkshire Surrey Pathology Services Virology laboratory to determine SARS-CoV-2 RNA levels. SARS-CoV-2 sequencing for variants was performed at Public Health England Colindale.

Patients in both trial groups started on NONS or placebo at least 4 days after the onset of symptoms and were well balanced in terms of risk factors (Table 1 ). There were no serious adverse events in patients within either trial group. The baseline mean SARS-CoV-2 load of ~2.4 x 10 7 RNA copies/mL of all participants corresponded with expectations of a high SARS-CoV-2 RNA burden. NONS versus placebo started on at least day 4 of symptom onset was independently associated with an accelerated decrease in log(10) SARS-CoV-2 RNA concentration of −1.21 (95% CI, −2.07 to −0.35; P=0.01) and −1.21 (95% CI, −2.19 to −0.24; P=0.02) on days 2 and 4 respectively (Figure 1 ). Mean SARS-CoV-2 RNA concentration was lower on NONS by a factor of 16.2 at days 2 and 4. A total of 46.7% (7 of 15) respondents on the NONS treatment arm reported feeling better versus 8% (2 of 25) of respondents on the placebo pathway.

Treatment with NONS in this trial was found to be effective in reducing the viral load in patients with mild, symptomatic COVID-19 infection. Patients in the NONS treatment arm demonstrated viral loads that were lower at days 2 and 4 by a factor of 16.2 than those on the placebo trial arm, and symptom resolution was also found to be faster on NONS than on placebo in this study. Accelerated SARS-CoV-2 clearance with NONS may reduce symptom duration, decrease infectivity period, reduce hospital admissions, and lower disease severity. This study could be used as supporting evidence for emergency use of NONS for patients with COVID-19 infection.

Shown is the difference in the change from baseline in SARS-CoV-2 RNA between the active (NONS) group and the placebo (saline) group from day 1 to day 6. The I bars represent standard error. The funder of the study conducted the randomisation of the anonymised participant data and provided the study supply materials. They otherwise had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. The researchers are not employed by SaNOtize Research & Development Corporation, Canada, and are independent of the funder.

Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: a longitudinal study

Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19

Endogenous nitric oxide: physiology, pathology and clinical relevance

Perspectives series: Host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity

Gaseous nitric oxide reduces influenza infectivity in vitro

Safety, bioavailability and mechanism of action of nitric oxide to control bovine respiratory disease complex in calves entering a feedlot